Table 1.
Data from a meta‐analysis of 17 trials comparing haloperidol with placebo for the treatment of schizophrenia 19.
| Trial | Placebo | Haloperidol | ||||||
|---|---|---|---|---|---|---|---|---|
| No. of events | No. missing | No. of complete cases | Total no. randomised | No. of events | No. missing | No. of complete cases | Total no. randomised | |
| i | r i,1 | m i,1 | c i,1 | n i,1 | r i,2 | m i,2 | c i,2 | n i,2 |
| i | r i,1 | m i,1 | c i,1 | n i,1 | r i,2 | m i,2 | c i,2 | n i,2 |
| 1 | 18 | 0 (0%) | 51 | 51 | 25 | 2 (4%) | 50 | 52 |
| 2 | 20 | 34 (50%) | 34 | 68 | 29 | 22 (32%) | 47 | 69 |
| 3 | 2 | 1 (3%) | 30 | 31 | 12 | 1 (3%) | 29 | 30 |
| 4 | 0 | 0 (0%) | 12 | 12 | 3 | 0 (0%) | 12 | 12 |
| 5 | 3 | 0 (0%) | 22 | 22 | 10 | 0 (0%) | 21 | 21 |
| 6 | 1 | 0 (0%) | 15 | 15 | 11 | 0 (0%) | 19 | 19 |
| 7 | 4 | 1 (4%) | 25 | 26 | 7 | 1 (4%) | 25 | 26 |
| 8 | 3 | 0 (0%) | 13 | 13 | 8 | 0 (0%) | 17 | 17 |
| 9 | 14 | 2 (3%) | 64 | 66 | 19 | 2 (3%) | 64 | 66 |
| 10 | 0 | 0 (0%) | 10 | 10 | 1 | 1 (10%) | 9 | 10 |
| 11 | 0 | 0 (0%) | 13 | 13 | 11 | 3 (8%) | 34 | 37 |
| 12 | 2 | 0 (0%) | 11 | 11 | 20 | 0 (0%) | 29 | 29 |
| 13 | 7 | 18 (62%) | 11 | 29 | 17 | 11 (38%) | 18 | 29 |
| 14 | 0 | 1 (7%) | 13 | 14 | 4 | 0 (0%) | 14 | 14 |
| 15 | 0 | 1 (13%) | 7 | 8 | 2 | 0 (0%) | 16 | 16 |
| 16 | 1 | 0 (0%) | 12 | 12 | 11 | 0 (0%) | 12 | 12 |
| 17 | 0 | 1 (3%) | 29 | 30 | 9 | 1 (3%) | 29 | 30 |